Research programme: infectious disease therapeutics - Johnson & Johnson

Drug Profile

Research programme: infectious disease therapeutics - Johnson & Johnson

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson
  • Developer Johnson & Johnson; National Institutes of Health (USA); University of California, San Diego; Walter and Eliza Hall Institute of Medical Research
  • Class Antimalarials; Antiparasitics; Antituberculars; Gene-directed enzyme-prodrug therapies; Small molecules
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Chagas disease; Malaria; Tuberculosis

Most Recent Events

  • 15 Jun 2017 Early research in Chagas'-disease in USA (unspecified route)
  • 15 Jun 2017 Early research in Malaria in USA (unspecified route)
  • 15 Jun 2017 Early research in Tuberculosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top